Non-Invasive and Accessible Testing system for Early Detection of Neurodegenerative Diseases.
Using Aβ amyloid and p-Tau concentrations detected in saliva to develop a machine learning-based system for identifying individuals at high risk of dementia
– The measurement of Aβ amyloid and p-Tau in saliva and the establishment of a robust validation system are vital for developing an accessible, non-invasive, and cost-effective diagnostic tool for early detection and monitoring of Alzheimer’s disease and other neurodegenerative disorders. This method could revolutionize the approach to dementia screening and care, enabling earlier intervention and better outcomes.
Long-Term Monitoring of Aβ amyloid and p-Tau in saliva for early detection
– The ability to easily measure Aβ amyloid and p-Tau in saliva supports personalized healthcare approaches.
– By tracking biomarker levels over time, healthcare providers can tailor interventions and monitor treatment effectiveness more precisely.
– For early detection of individuals at high risk of dementia.
Detecting Aβ amyloid and p-Tau concentrations in saliva and integrating this data into a machine learning system offers a non-invasive, cost-effective method
